Valuation: Haleon plc

Market Cap 33.58B 44.92B 40.11B 37.05B 62.82B 4,264B 63.86B 446B 177B 2,234B 169B 165B 7,043B P/E 2026 *
19.7x
P/E 2027 * 17.5x
Enterprise Value 40.47B 54.13B 48.34B 44.66B 75.72B 5,139B 76.97B 537B 213B 2,692B 203B 199B 8,489B EV / Sales 2026 *
3.55x
EV / Sales 2027 * 3.35x
Free-Float
98.46%
Yield 2026 *
2.12%
Yield 2027 * 2.34%

Last Transcript: Haleon plc

1 day-0.39%
1 week+1.63%
Current month+12.91%
1 month+11.59%
3 months+5.42%
6 months+8.42%
Current year+1.71%
1 week 372.6
Extreme 372.6
383.8
1 month 324.8
Extreme 324.8
433.6
Current year 317.8
Extreme 317.8
433.6
1 year 317.8
Extreme 317.8
433.6
3 years 274.4
Extreme 274.4
433.6
5 years 241.17
Extreme 241.1735
433.6
10 years 241.17
Extreme 241.1735
433.6
Manager TitleAgeSince
Chief Executive Officer 59 22/07/2021
Director of Finance/CFO 58 01/11/2024
Chief Tech/Sci/R&D Officer 63 01/08/2025
Director TitleAgeSince
Director/Board Member 59 23/05/2022
Chairman 71 01/01/2026
Director/Board Member 59 18/07/2022
Date Insider Type Main position Quantity % Market Cap. Importance
22/09/26 Buy 2,139 0.0000%
22/09/26 Buy 12,209 0.0001%
22/09/26 Buy

Chief Financial Officer

2,317 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%+1.63%+8.54%+13.44% 44.92B
-2.54%+1.31%+55.10%+120.84% 1,135B
-1.42%+3.23%+37.07%+74.26% 636B
+0.16%+0.08%+25.14%+97.36% 505B
-0.31%+3.09%+43.92%+64.55% 378B
-1.34%-0.47%+66.63%+40.56% 358B
-0.68%+2.65%+22.46%+51.48% 295B
-1.20%+3.04%+2.62%+26.97% 266B
-1.79%+1.57%+49.97%+60.87% 237B
-0.73%-0.10%+29.24%+101.19% 193B
Average -0.64%+2.11%+34.07%+65.15% 404.93B
Weighted average by Cap. -0.26%+2.65%+40.63%+81.37%

Financials

2026 *2027 *
Net sales 11.39B 15.24B 13.61B 12.57B 21.32B 1,447B 21.67B 151B 59.9B 758B 57.19B 55.98B 2,390B 11.87B 15.88B 14.18B 13.1B 22.21B 1,507B 22.57B 158B 62.4B 790B 59.58B 58.32B 2,490B
Net income 1.72B 2.31B 2.06B 1.9B 3.23B 219B 3.28B 22.89B 9.06B 115B 8.66B 8.47B 362B 1.93B 2.58B 2.31B 2.13B 3.61B 245B 3.67B 25.65B 10.16B 129B 9.7B 9.49B 405B
Net Debt 6.89B 9.22B 8.23B 7.6B 12.89B 875B 13.11B 91.51B 36.23B 458B 34.59B 33.86B 1,445B 6.21B 8.3B 7.41B 6.85B 11.61B 788B 11.8B 82.41B 32.63B 413B 31.16B 30.49B 1,302B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
23/10/26 GBX 381.20 -0.39% 19,235,928
22/10/26 GBX 382.70 +2.71% 30,318,935
21/10/26 GBX 372.60 -0.88% 32,986,983
20/10/26 GBX 375.90 -0.29% 29,055,238
19/10/26 GBX 377.00 +0.51% 23,936,647
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.812GBP
Average target price
4.179GBP
Spread / Average Target
+9.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Haleon plc